Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. (VIR) common stock is the subject of BlackRock, Inc.’s amended report, which states beneficial ownership of 20,905,681 shares, or 12.4% of the class.
BlackRock reported sole voting power over 20,560,285 shares and sole dispositive power over 20,905,681 shares, with no shared voting or dispositive power. The report covers securities held or deemed held by certain BlackRock business units and subsidiaries or affiliates. It states that various persons may receive dividends or sale proceeds, but no one person’s interest is more than 5% of the class.
Vir Biotechnology, Inc. (VIR) entered a global collaboration with Gilead Sciences on October 9, 2026, to discover and engineer three PRO-XTEN® dual-masked T-cell engager development candidates for selected solid tumor-associated antigens. Vir will handle discovery, design and optimization; Gilead will have an exclusive license to nominate and advance candidates and will handle subsequent development, manufacturing and commercialization.
Vir is eligible for up to $135 million in upfront and near-term preclinical milestone payments: $90 million in upfront consideration, including $65 million cash and a $25 million equity investment, plus up to $45 million in potential near-term milestones. Gilead agreed to purchase 1,765,486 common shares at $14.16 per share, for approximately $25 million, subject to customary closing conditions; the equity investment is at a 30% premium. Vir may also receive up to $1.74 billion in further development, regulatory and commercial milestones, plus tiered high single-digit to low double-digit royalties on net sales.
Vir Biotechnology, Inc. (VIR) said the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC). The candidate is being co-developed with Astellas Pharma Inc. through a global strategic collaboration. Fast Track is intended to facilitate and expedite development and review of drugs for serious conditions that fill an unmet need.
VIR-5500 is being evaluated in a Phase 1 study across six dose-expansion cohorts, including monotherapy and combination regimens. Vir said Phase 1 data reported earlier this year showed the candidate was generally well tolerated and exhibited promising anti-tumor activity in patients with mCRPC. Phase 3 trials are anticipated to begin in 2027.
Vir Biotechnology, Inc. (VIR) EVP and Chief Financial Officer Aziz Sawaf reported a direct Common Stock position of 0 shares on October 5, 2026. The entry reports a holding, not a purchase, sale, grant, or exercise.
Vir Biotechnology, Inc. appointed Aziz Sawaf, MBEE, MBA, CFA, as executive vice president and chief financial officer, effective October 5, 2026. Brent Sabatini will stop serving as interim principal financial officer on that date and continue as senior vice president and chief accounting officer. Sawaf previously served as CFO of Theravance Biopharma since 2023.
Sawaf will receive an annualized base salary of $520,000 and is eligible for an annual bonus targeted at 45% of base salary. His $150,000 sign-on bonus will be paid in two halves: one on or around the effective date and one following its one-year anniversary, subject to continued employment through each payment date. On or around November 15, 2026, Vir has agreed to grant him an option for 150,000 shares and 75,000 restricted stock units. Both awards vest over four years, subject to continued employment; the option’s exercise price will equal fair market value on the grant date.
Vir Biotechnology, Inc. (VIR) is the issuer for a proposed sale by former officer Jason V. O'Byrne of 19,357 common shares, with an aggregate market value of $212,927.00 and an approximate sale date of September 17, 2026. During the past three months, O'Byrne also sold 25,000 common shares on August 21, 2026, for gross proceeds of $245,297.50; 14,352 common shares on August 24, 2026, for $142,123.55; 23,148 common shares on August 25, 2026, for $242,591.04; and 28,333 common shares on September 9, 2026, for $315,241.46.
Vir Biotechnology, Inc. (VIR) received a notice under Rule 144 that former officer Jason V. O'Byrne, through Fidelity Brokerage Services LLC, intends to sell 28,333 shares of common stock, expected to be issued from a stock option exercise on September 9, 2026. The filing lists an estimated aggregate sale price of $315,241.24 and states that 169,215,958 shares of common stock were outstanding as of September 9, 2026.
The notice also reports prior sales of Vir common stock for O'Byrne during the past three months, including transactions on August 21, 24, and 25, 2026.
Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by Jason V. O'Byrne, identified as a former officer, under Rule 144. The notice covers up to 23,148 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $242,591.04. Vir Biotechnology reports 169,215,958 shares of common stock outstanding as of 08/25/2026. In the prior three months, Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. The planned sale is in connection with a stock option exercise, with sales expected on or about 08/25/2026 on NASDAQ.
Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by former officer Jason V. O'Byrne under Rule 144. The notice lists up to 14,352 shares of common stock to be sold, with an aggregate market value of $142,124.00, following a stock option exercise for cash on 08/24/2026. The securities are held at Fidelity Brokerage Services LLC and are listed on NASDAQ. The notice also reports that O'Byrne sold 25,000 shares of Vir common stock during the past three months for proceeds of $245,297.50.
Vir Biotechnology, Inc. (VIR) is the issuer of common stock that a former officer, Jason V. O'Byrne, has notified under Rule 144 may be sold. The notice covers up to 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or after 08/21/2026, in connection with a stock option exercise.